Guardant Health Provides Update on COBRA Study, Restates Confidence in MRD Test
01 Setembro 2023 - 4:46PM
Business Wire
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology
company, today issued the following statement about the closure of
COBRA, a minimum residual disease (MRD) study.
The COBRA study was designed to evaluate the effectiveness of
using MRD testing to improve clinical outcomes in patients with
stage II colon cancer after curative-intent surgery with a planned
final readout in 2026.
“Our MRD test has great potential to help patients and their
doctors stay ahead of cancer, and we remain confident about its
promise to vastly improve patient care and its continued prospects
for broad access and reimbursement,” said Craig Eagle, MD, Guardant
Health chief medical officer.
“We agree with the decision, based on the recent planned interim
analysis, to close the COBRA study to new enrollees,” said Dr.
Eagle. “The field has progressed rapidly since the study was
designed over four years ago, and since the study was initiated we
have made tremendous progress with multiple upgrades of our MRD
test. Additionally, we have many ongoing studies that will
demonstrate the effectiveness of our current MRD tests in
colorectal cancer and other settings.”
About Guardant Health
Guardant Health is a leading precision oncology company focused
on helping conquer cancer globally through use of its proprietary
tests, vast data sets and advanced analytics. The Guardant Health
oncology platform leverages capabilities to drive commercial
adoption, improve patient clinical outcomes and lower healthcare
costs across all stages of the cancer care continuum. Guardant
Health has commercially launched Guardant360®, Guardant360 CDx,
Guardant360 TissueNext™, Guardant360 Response™, and
GuardantINFINITY™ tests for advanced stage cancer patients, and
Guardant Reveal™ for early-stage cancer patients. The Guardant
Health screening portfolio, including the Shield™ test, aims to
address the needs of individuals eligible for cancer screening. For
more information, visit guardanthealth.com and follow the company
on LinkedIn and Twitter (X).
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of federal securities laws, including statements
regarding the potential utilities, values, benefits and advantages
of Guardant Health’s liquid biopsy tests or assays, which involve
risks and uncertainties that could cause the actual results to
differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are
based on current expectations, forecasts and assumptions, and
actual outcomes and results could differ materially from these
statements due to a number of factors. These and additional risks
and uncertainties that could affect Guardant Health’s financial and
operating results and cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release include those discussed under the captions “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operation” and elsewhere in its Annual
Report on Form 10-K for the year ended December 31, 2022, and any
current and periodic reports filed with or furnished to the
Securities and Exchange Commission thereafter. The forward-looking
statements in this press release are based on information available
to Guardant Health as of the date hereof, and Guardant Health
disclaims any obligation to update any forward-looking statements
provided to reflect any change in its expectations or any change in
events, conditions, or circumstances on which any such statement is
based, except as required by law. These forward-looking statements
should not be relied upon as representing Guardant Health’s views
as of any date subsequent to the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230901319507/en/
Investor Contact: investors@guardanthealth.com
Media Contact: Matt Burns press@guardanthealth.com +1 518
423 5907
Guardant Health (NASDAQ:GH)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Guardant Health (NASDAQ:GH)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024